Dr. Ruan on the Incidence of MCL

Video

In Partnership With:

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the incidence of mantle cell lymphoma (MCL).

MCL is a rare subtype of B-cell non-Hodgkin lymphoma (NHL), says Ruan. In North America, MCL occurs in approximately 5% to 6% of new patients diagnosed with NHL.

Moreover, the disease tends to affect older patients, Ruan explains. The median age of patients who receive a diagnosis of MCL is 65 years.

Within the past decade, the MCL paradigm has expanded to include multiple new treatment options, Ruan says. These therapies have greatly improved survival for patients in this population.

Despite these advances, patients with MCL remain in need of additional therapies to further prolong survival, concludes Ruan.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD